ChemPartner PharmaTech Co

ChemPartner PharmaTech Co Forward P/E

The Forward P/E Ratio of ChemPartner PharmaTech Co (300149.SZ) as of Oct 27, 2026 is 425.01. In the previous year, Forward P/E Ratio was -25.17 — a change of -1,788.58% (higher).

Forward P/E

425.01

YoY

-1,788.58%

Last updated:

Forward P/E Ratio of ChemPartner PharmaTech Co is 2025 425.01 . Forward P/E Ratio of ChemPartner PharmaTech Co was 2024 -25.17 . It decreases by -1,788.58% higher compared to the previous year.

The ChemPartner PharmaTech Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
35.39 CNY
Jan 1, 2019
41.03 CNY
Jan 1, 2020
36.88 CNY
Jan 1, 2021
-14.17 CNY
Jan 1, 2022
15.06 CNY
Jan 1, 2023
-6.22 CNY
Jan 1, 2024
-25.17 CNY
Jan 1, 2025
425.01 CNY
The ChemPartner PharmaTech Co Forward P/E history
YEARForward P/EYoY
425.01-1,788.58%
-25.17+304.79%
-6.22-141.30%
15.06-206.25%
-14.17-138.42%
36.88-10.11%
41.03+15.95%
35.39-64.11%
98.61+12.41%
87.72-8.48%
95.85-31.57%
140.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ChemPartner PharmaTech Co Stock analysis

What does ChemPartner PharmaTech Co do? ChemPartner PharmaTech Co., Ltd. generates revenue through the research, development, production, and sale of prebiotic products, primarily fructooligosaccharides and galactooligosaccharides. The company markets its products under the brand names FOS and GOS, targeting the nutrition and health, dairy, beverage, bakery, and functional snack food industries. Domestic distribution dominates, with South China as the core market, serving manufacturers of food and health products. The firm's product portfolio focuses on fructooligosaccharides and galactooligosaccharides, sold as FOS and GOS, which are integrated into various consumer goods. These prebiotics are essential ingredients in dairy, beverages, baked goods, and functional snacks, meeting demand from food producers seeking health-enhancing additives. South China remains the primary sales region, aligning with the company's domestic market strategy. ChemPartner PharmaTech's revenue streams derive from B2B sales to food and beverage manufacturers, particularly those producing nutrition and health products, dairy, and functional snacks. The company's brands FOS and GOS are positioned as key ingredients for health-focused consumer goods, with sales concentrated in South China, the main market for its domestic distribution network. ChemPartner PharmaTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ChemPartner PharmaTech Co stock

Forward P/E Ratio of ChemPartner PharmaTech Co is 425.01 in 2025.

Forward P/E Ratio of ChemPartner PharmaTech Co changed from -25.17 to 425.01, representing a -1,788.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio ChemPartner PharmaTech Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's ChemPartner PharmaTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ChemPartner PharmaTech Co

All Key Metrics — ChemPartner PharmaTech Co